Ebola in Congo, WHO emergency committee meets in Geneva

On August 18, 2026, the meeting of the World Health Organization’s emergency committee on the Ebola epidemic in the Democratic Republic of the Congo is convened in Geneva, according to the schedule of events published by ANSA. This is the body provided for under the International Health Regulations that assesses whether the conditions of the declared emergency persist and with what recommendations to States.

The numbers, and what they measure

According to WHO data reported in the Disease Outbreak News and cited by Adnkronos, as of July 30, 2026, 3,605 confirmed cases and 1,587 deaths had been recorded, with a crude case fatality rate of 44%. The organization describes the dynamic with a dry formula: “The outbreak is intensifying, with sustained transmission.”

Two caveats must be stated regarding these figures. The first: these are confirmed cases, meaning those that have undergone laboratory confirmation, a category that by definition does not coincide with the total number of infections that have occurred. The second: the fatality rate indicated is “crude,” meaning the ratio between deaths and cases recorded as of a given date — an indicator that in an ongoing epidemic can shift as the outcomes of recent cases are classified.

The public health emergency of international concern was declared on May 17, 2026, with a risk assessment of “high” for sub-Saharan Africa and “low” on a global scale. The geographic distribution is heavily concentrated: the Ituri province accounts for approximately 90% of infections and over 83% of deaths, as reported by Mondo Sanità based on WHO and ECDC documents. The ECDC published its own epidemiological update on the epidemic in the Democratic Republic of the Congo and Uganda in August 2026.

Unicef data reported by Famiglia Cristiana indicate that, as of August 2, 2026, there were 743 confirmed cases in the 0-17 age group and 330 deaths in the same group: approximately one-fifth of the total confirmed cases.

Why this strain is different

The responsible agent is the Bundibugyo ebolavirus, a rarer strain compared to the Zaire ebolavirus. The difference is not merely nominal: no approved vaccines exist against Bundibugyo. The tools built during previous epidemics — and the response logistics that rely on them — are therefore not directly available.

On the research front, two vaccines specific to Bundibugyo have entered phase 1 trials for the first time, while the study named PARTNERS is examining the monoclonal antibody MBP134 and the antiviral remdesivir. Caution is required here, and it must be stated in the text and not in the footnotes: phase 1 is the stage in which safety and tolerability are assessed in a limited number of participants, not protective efficacy. A vaccine in phase 1 is not an available vaccine, and none of the products mentioned is approved for this strain. The available material does not report sample sizes, protocols, or any conflicts of interest declared in the studies.

What Geneva can decide

The emergency committee does not distribute resources: it provides an opinion to the director-general on whether to maintain, modify, or revoke the international emergency and on temporary recommendations to States — surveillance measures, entry point controls, response coordination. The binding force of these indications is limited, though their effect on response funding has historically not been.

The number to compare after the meeting is the updated count of confirmed cases relative to the 3,605 recorded on July 30: it is the measure of how much transmission has slowed in the following three weeks.